Four biologics beat placebo in palmoplantar psoriasis, on indirect comparison

The edition in brief

A Bayesian network meta-analysis of 20 randomised trials (2,158 patients) found that adalimumab, guselkumab 100 mg, ixekizumab and secukinumab beat placebo for palmoplantar psoriasis or pustulosis at weeks 14 to 16; ixekizumab ranked highest (SUCRA 87.2%), but the comparisons are indirect and the populations varied. A second network meta-analysis (eight studies, 4,319 patients) found that all biologic classes improved depression and anxiety symptoms against placebo in moderate to severe plaque psoriasis, with improvement in mood generally accompanying skin response. A systematic review of 54 studies of imaging-based AI for vitiligo reported diagnostic AUC above 0.90 and segmentation Dice 0.84, often matching experts, but datasets are small and not diverse. In a randomised double-blind trial of 453 patients, repeated switching between the ustekinumab biosimilar ABP 654 and the reference product gave similar exposure (AUCtau ratio 0.93, 90% CI 0.89 to 0.98), efficacy, antidrug antibodies and adverse events.